Genzyme Corporation More Willing to Talk to Sanofi-Aventis (France)

BOSTON (Reuters) - Genzyme Corp (GENZ.O) is more willing to discuss price with Sanofi-Aventis SA (SASY.PA), which is trying to acquire the U.S. biotechnology company for $18.5 billion, or $69 a share, according to the Wall Street Journal.